These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29125592)

  • 21. Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients.
    Ohta Y; Yamashita T; Nomura E; Hishikawa N; Ikegami K; Osakada Y; Matsumoto N; Kawahara Y; Yunoki T; Takahashi Y; Takamiya M; Tadokoro K; Sasaki R; Nakano Y; Tsunoda K; Sato K; Omote Y; Takemoto M; Abe K
    J Neurol Sci; 2020 Aug; 415():116906. PubMed ID: 32446009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
    Abe K; Itoyama Y; Sobue G; Tsuji S; Aoki M; Doyu M; Hamada C; Kondo K; Yoneoka T; Akimoto M; Yoshino H;
    Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):610-7. PubMed ID: 25286015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch.
    Jackson C; Heiman-Patterson T; Kittrell P; Baranovsky T; McAnanama G; Bower L; Agnese W; Martin M
    Amyotroph Lateral Scler Frontotemporal Degener; 2019 Nov; 20(7-8):605-610. PubMed ID: 31364409
    [No Abstract]   [Full Text] [Related]  

  • 25. Edaravone Mitsubishi-Tokyo.
    Tabrizchi R
    Curr Opin Investig Drugs; 2000 Nov; 1(3):347-54. PubMed ID: 11249718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger.
    Aoki M; Warita H; Mizuno H; Suzuki N; Yuki S; Itoyama Y
    Brain Res; 2011 Mar; 1382():321-5. PubMed ID: 21276427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction.
    Tsujita K; Shimomura H; Kawano H; Hokamaki J; Fukuda M; Yamashita T; Hida S; Nakamura Y; Nagayoshi Y; Sakamoto T; Yoshimura M; Arai H; Ogawa H
    Am J Cardiol; 2004 Aug; 94(4):481-4. PubMed ID: 15325934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials.
    Yang J; Cui X; Li J; Zhang C; Zhang J; Liu M
    Dev Neurorehabil; 2015; 18(5):330-5. PubMed ID: 24088023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Edaravone: A new drug approved for ALS.
    Rothstein JD
    Cell; 2017 Nov; 171(4):725. PubMed ID: 29100067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Oral Form for ALS Drug.
    Aschenbrenner DS
    Am J Nurs; 2022 Sep; 122(9):24-25. PubMed ID: 36005791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
    Ikeda K; Iwasaki Y
    PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New treatment of free-radical scavenger in adrenoleukodystrophy.
    Kawashima H; Nishimata S; Ishii C; Yamanaka G; Kashiwagi Y; Takekuma K; Hoshika A; Watanabe Y
    J Clin Pharm Ther; 2011 Jun; 36(3):412-5. PubMed ID: 21463348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters.
    Edaravone Acute Infarction Study Group
    Cerebrovasc Dis; 2003; 15(3):222-9. PubMed ID: 12715790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial).
    Shinohara Y; Saito I; Kobayashi S; Uchiyama S
    Cerebrovasc Dis; 2009; 27(5):485-92. PubMed ID: 19321945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Edaravone in acute ischemic stroke.
    Kitagawa Y
    Intern Med; 2006; 45(5):225-6. PubMed ID: 16595983
    [No Abstract]   [Full Text] [Related]  

  • 37. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
    Tanahashi N; Yamaguchi T; Awano H; Matsuda H
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1302-1310. PubMed ID: 29373227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The novel antioxidant edaravone: from bench to bedside.
    Watanabe T; Tahara M; Todo S
    Cardiovasc Ther; 2008; 26(2):101-14. PubMed ID: 18485133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Edaravone for treatment of early-stage ALS.
    Mora JS
    Lancet Neurol; 2017 Oct; 16(10):772. PubMed ID: 28920880
    [No Abstract]   [Full Text] [Related]  

  • 40. Edaravone: a new treatment for ALS on the horizon?
    Hardiman O; van den Berg LH
    Lancet Neurol; 2017 Jul; 16(7):490-491. PubMed ID: 28522180
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.